U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269626) titled 'PULSAR in Systemic Therapy for Pancreatic Cancer' on Nov. 25.
Brief Summary: Pancreatic cancer remains one of the malignancies with the lowest survival rates, largely due to late-stage diagnosis and the difficulty of achieving curative resection. A substantial proportion of patients present with locally advanced, unresectable disease at the time of diagnosis, making intensive systemic therapy the current standard of care. For selected patients, radiation therapy (RT) is integrated to improve local control. Local progression in the pancreas can lead to severe complications, including intractable pain, gastric outlet obstruction, and b...